Inhibition of cardiac fibrosis by colchicine in acute myocardial infarction

Inhibition of cardiac fibrosis by colchicine through differential increase in interleukin-10 and galectin-3 expression and decrease in the ratio of collagen I to collagen III and NT-proBNP in acute myocardial infarction (in vivo study on patients with acute myocardial infarction with ST-segment elevation undergoing primary and delayed percutaneous coronary intervention)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN12958502

Enrollment

300

Registered

2024-01-02

Start date

2022-09-20

Completion date

Unknown

Last updated

2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction Circulatory System

Interventions

Patients undergoing primary and delayed percutaneous coronary intervention (PCI) are divided into two groups for each PCI type. Sample selection is through consecutive sampling, and randomization is 1

Eligibility

Sex/Gender

All

Age

30 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with STEMI for the first time, with the following diagnostic criteria: persistent typical chest pain >30 minutes lasting more than 12 hours, accompanied by ST-segment elevation in at least 2 contiguous leads, and an increase in cardiac enzymes, troponin I. 2. Patients who have received information about the study and signed an informed consent. 3. Patients not pregnant, breastfeeding, or planning pregnancy during the study period. 4. Patients without a history of alcohol abuse. 5. Patients not receiving long-term steroid therapy during the study. 6. Patients not currently taking colchicine for other indications (e.g., gout arthritis, familial Mediterranean fever).

Exclusion criteria

Exclusion criteria: 1. Patients with poor medication adherence, as evidenced by the number of missed doses during the study. 2. Patients with a history of hypersensitivity to colchicine. 3. Patients with comorbidities such as infections, inflammation, malignancy, for instance, irritable bowel syndrome (Crohn's Disease or ulcerative colitis), severe renal failure (eGFR 3 times the upper normal limit, Total Bilirubin > 2 times the upper normal limit, Creatinine > 2 times the upper normal limit. 5. Patients who have experienced cardiac arrest. 6. Patients with ventricular fibrillation. 7. Patients with cardiogenic shock or unstable hemodynamics.

Design outcomes

Primary

Measure	Time frame
Left ventricular remodelling measured using echocardiography during hospitalization and 1 month post-hospitalization	—

Secondary

Measure	Time frame
Biomarkers (Gal3, IL10, PIIINP and NTProBNP) measured during hospitalization and 1 month post-hospitalization	—

Countries

Indonesia

Contacts

Public ContactSaskia Dyah Handari

saskiadyahandari@gmail.com+62-81332879978

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 19, 2026